Immediate Impact
31 standout
Citing Papers
European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update
2024 Standout
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
2024 Standout
Works of David E. Brooks being referenced
LBA27 PHASE 3 STUDY OF VICINIUM IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: INITIAL RESULTS
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| David E. Brooks | 30 | 22 | 5 | 16 | 10 | 141 | |
| Henk van den Belt | 27 | 27 | 1 | 11 | 169 | ||
| David W. Walters | 71 | 7 | 6 | 8 | 231 | ||
| Frank Busing | 21 | 67 | 2 | 2 | 15 | 228 | |
| Danli Liu | 79 | 47 | 8 | 14 | 247 | ||
| Brian L. Hawkins | 81 | 12 | 3 | 6 | 14 | 223 | |
| X Fu | 23 | 14 | 5 | 5 | 19 | 183 | |
| Jian Chen | 20 | 12 | 3 | 8 | 244 | ||
| David L. Rainey | 22 | 12 | 9 | 129 | |||
| Haiyang Jia | 96 | 7 | 1 | 3 | 16 | 211 | |
| Svenja Jarchow | 31 | 26 | 14 | 117 |
All Works
Loading papers...